Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children

Gadi Howard, Dror Weiner, Itzhak Bar-Or, Arie Levine*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.

Original languageEnglish
Pages (from-to)372-374
Number of pages3
JournalEuropean Journal of Gastroenterology and Hepatology
Volume34
Issue number4
DOIs
StatePublished - 1 Apr 2022

Keywords

  • Crohn's disease
  • dual biologic therapy
  • multidrug refractory Crohn's

Fingerprint

Dive into the research topics of 'Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children'. Together they form a unique fingerprint.

Cite this